Discontinuation report DAKLINZA
| Report ID | 62549 |
| Drug Identification Number | 02444747 |
| Brand name | DAKLINZA |
| Common or Proper name | daclatasvir dihydrochloride |
| Company Name | BRISTOL-MYERS SQUIBB CANADA |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | Daclatasvir |
| Strength(s) | 30MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 1 Bottle X 28 |
| ATC code | J05AP |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2019-07-31 |
| Actual discontinuation date | |
| Remaining supply date | 2019-07-31 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | Stock will be available until July 31st, 2019 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2344 BOUL. ALFRED-NOBEL, SUITE 300 ST-LAURENT, QUEBEC CANADA H4S 0A4 |
| Company contact information | For more information please contact the Customer Service Desk at 1-800-267-0005 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2018-09-28 | French | Compare |
| v4 | 2018-09-28 | French | Compare |
| v3 | 2018-09-28 | English | Compare |
| v2 | 2018-09-28 | English | Compare |
| v1 | 2018-09-28 | English | Compare |
Showing 1 to 5 of 5